Galera Therapeutics (NASDAQ:GRTX) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 51,700 shares, a drop of 8.7% from the January 15th total of 56,600 shares. Based on an average daily volume of 112,400 shares, the short-interest ratio is presently 0.5 days. Approximately 0.7% of the shares of the stock are sold short.
Shares of GRTX traded down $0.09 during midday trading on Friday, hitting $13.95. The company’s stock had a trading volume of 6,355 shares. Galera Therapeutics has a one year low of $8.16 and a one year high of $19.50. The company’s fifty day moving average price is $13.79.
Galera Therapeutics (NASDAQ:GRTX) last issued its quarterly earnings results on Tuesday, December 10th. The company reported ($51.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($50.98). On average, equities analysts expect that Galera Therapeutics will post -1.92 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in shares of Galera Therapeutics during the 4th quarter valued at $28,000. UBS Group AG acquired a new stake in shares of Galera Therapeutics during the 4th quarter valued at $45,000. Perceptive Advisors LLC acquired a new stake in shares of Galera Therapeutics during the 4th quarter valued at $4,277,000. RA Capital Management L.P. acquired a new stake in shares of Galera Therapeutics during the 4th quarter valued at $13,873,000. Finally, Blackstone Group Inc acquired a new stake in shares of Galera Therapeutics during the 4th quarter valued at $22,095,000. 17.59% of the stock is currently owned by institutional investors.
Galera Therapeutics Company Profile
Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.
Featured Story: What are different types of coverage ratios?
Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.